Eichenfield LF, Beck L: Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. .J Allergy Clin Immunol 5::1153. ,2003. .
Sussman C, Bates-Jensen BM: “Wound Healing Physiology: Acute and Chronic,” in Wound Care: A Collaborative Practice Manual for Health Professionals, 3rd Ed, p 21, Lippincott Williams & Wilkins, Philadelphia. ,2007. .
FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic. Available at: http://www.fda.gov/bbs/topics/news/2006/NEW01299.html. Accessed February 19. ,2008. .
Fonacier L, Spergel J, Charlesworth EN, et al: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. .J Allergy Clin Immunol 6::1249. ,2005. .
Fonacier L, Charlesworth EN, Spergel JM, et al: The black box warning for topical calcineurin inhibitors: looking outside the box. .Ann Allergy Asthma Immunol 1::117. ,2006. .
Berger TG, Duvic M, Van Voorhees AS, et al: American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. .J Am Acad Dermatol 5::818. ,2006. .
Ring J, Barker J, Behrendt H, et al: Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. .J Eur Acad Dermatol Venereol 6::663. ,2005. .
Stern RS: Topical calcineurin inhibitors labeling: putting the “box” in perspective. .Arch Dermatol 9::1233. ,2006. .